Does Rallies show Form 4 insider transactions for ORGO?

Yes. Rallies tracks ORGO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ORGO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ORGO. It does not provide personalized investment advice.

ORGO (Organogenesis Holdings Inc. Class A Common Stock) Stock Analysis - Insider Trades

Organogenesis Holdings Inc. Class A Common Stock (ORGO) is a publicly traded Healthcare sector company. As of May 21, 2026, ORGO trades at $2.55 with a market cap of $319.11M and a P/E ratio of 15.59. ORGO moved +5.35% today. Year to date, ORGO is -42.18%; over the trailing twelve months it is -21.78%. Its 52-week range spans $2.04 to $7.08. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces ORGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ORGO stock inside the company?

Recent ORGO insider activity includes Leibowitz Arthur S bought 5.00K, Driscoll Michael Joseph bought 10.00K, NUSSDORF GLENN H sold 200.00K, NUSSDORF GLENN H sold 187.96K, and NUSSDORF GLENN H sold 12.04K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ORGO Key Metrics

Key financial metrics for ORGO
Metric	Value
Price	$2.55
Market Cap	$319.11M
P/E Ratio	15.59
EPS	$0.16
Dividend Yield	0.00%
52-Week High	$7.08
52-Week Low	$2.04
Volume	0
Avg Volume	0
Revenue (TTM)	$564.17M
Net Income	$37.03M
Gross Margin	0.00%

Recent ORGO Insider Trades

Leibowitz Arthur S bought 5.00K (~$13.40K) on Mar 9, 2026.
Driscoll Michael Joseph bought 10.00K (~$26.69K) on Mar 9, 2026.
NUSSDORF GLENN H sold 200.00K (~$1.03M) on Dec 16, 2025.
NUSSDORF GLENN H sold 187.96K (~$994.29K) on Nov 26, 2025.
NUSSDORF GLENN H sold 12.04K (~$63.83K) on Nov 25, 2025.

Latest ORGO News

Organogenesis Q1 Revenue Falls 58% to $36.3M, Loss Widens to $53.2M — May 7, 2026
Organogenesis Completes FDA BLA Submission for ReNu Knee OA Allograft — Apr 28, 2026
Organogenesis Trial Demonstrates Statistically Significant DFU Closure in 12 Weeks — Apr 7, 2026
Organogenesis’ PuraPly AM Shows Statistically Significant Ulcer Closure in 170-Patient Trial — Apr 6, 2026
Organogenesis Plans Rolling BLA Submission for ReNu by End-2025 After FDA Meeting — Apr 6, 2026

ORGO Analyst Consensus

1 analysts cover ORGO: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.

Common questions about ORGO

Who is trading ORGO stock inside the company?: Recent ORGO insider activity includes Leibowitz Arthur S bought 5.00K, Driscoll Michael Joseph bought 10.00K, NUSSDORF GLENN H sold 200.00K, NUSSDORF GLENN H sold 187.96K, and NUSSDORF GLENN H sold 12.04K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ORGO?: Yes. Rallies tracks ORGO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ORGO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ORGO. It does not provide personalized investment advice.